Insilico Biotechnology has joined the Inno4vac project—an innovative European public-private partnership aimed at accelerating vaccine R&D timelines.
Insilico Biotechnology has joined the Inno4vac project, which is an innovative European public-private partnership aimed at accelerating vaccine R&D timelines. Insilico’s participation in the project was announced in an Aug. 24, 2021 press release.
Inno4vac is an interdisciplinary project that is being backed by funding from the Innovative Medicines Initiative 2 (IMI2), which aims to foster health innovation through incorporating scientific and technological breakthrough from both academia and the biotech sector into industry. The project is being coordinated by the European Vaccine Initiative (Germany), with the support from the Sclavo Vaccines Association (Italy), for the scientific coordination. Additionally, 41 partners from 11 European countries are involved in the project.
“The scientific community has recognized the urgent need to significantly reduce the time-to-market for new vaccines, as required by the continued advance of infectious diseases,” said Klaus Mauch, CEO of Insilico, in the press release. “Therefore, Insilico is excited to be part of the Inno4vac partnership and to work with renowned partners who will make use of Insilico’s latest technology platform and modeling experience to accelerate the availability of new vaccines.”
Insilico’s role in the project will involve the creation and validation of digital twins for cell cultivation, so that innovative solutions for scaling up and controlling vaccine production in large-scale plants can be developed along with academic and industrial partners.